Table 1 Patient demographics.
Variable | n=463 |
|---|---|
Median age (range) | 68 (31–89) |
Sex ratio (M:F) | 1.4:1 |
Pathway | |
Intensive | 262 (57%) |
Non-intensive | 201 (43%) |
Isotype | |
IgA | 121 (26%) |
IgD | 8 (1.7%) |
IgG | 263 (57%) |
Light chain only | 55 (12%) |
Non-secretors | 2 (1%) |
Data missing | 14 (3%) |
International Staging System (ISS) | |
I | 140 (30%) |
II | 135 (29%) |
III | 159 (34%) |
II+III | 294 (63%) |
Data missing | 29 (6%) |
Beta-2-microglobulin | |
≤3.5 mg l−1 | 153 (33%) |
3.5<–<5.5 mg l−1 | 119 (26%) |
≥5.5 mg l−1 | 162 (35%) |
Data missing | 29 (6%) |
Creatinine | |
≥104 μmol l−1 | 162 (35%) |
≥150 μmol l−1 | 57 (13%) |
Bone disease | 324 (70%) |
Hypercalcaemia ≥2.65 mmol l−1 | 58 (12.5%) |
Copy number abnormality (gene) | |
del(1p33) (FAF1/CDNK2C) | 39 (8.5%) |
del(1p12) (FAM46C) | 111 (24%) |
gain(1q21.2) (CKS1B) | 166 (36%) |
del(13q) (RB1) | 195 (42%) |
del(17p) (TP53) | 44 (9.5%) |
Hyperdiploidy | 239 (52%) |
Translocations | |
t(4;14) | 59 (12.7%) |
t(6;14) | 5 (1%) |
t(11;14) | 86 (18.6%) |
t(14;16) | 17 (4%) |
t(14;20) | 4 (1%) |
